Join us for an insightful “Ask the Author Session” welcoming Professor Gregory Steinberg, working at McMaster University, where he serves as a professor of medicine and director of the Center of Metabolism, Obesity and Diabetes. Professor Steinberg discusses his very interesting and really great paper published recently in Nature, titled “ACLY Inhibition Promotes Tumor Immunity
Solving the Second-Line Mystery in HCC: Why the LEVIATHAN Study Changes Everything
For patients fighting hepatocellular carcinoma (HCC), the current standard first-line treatment is typically immuno-oncology, specifically atezolizumab plus bevacizumab (A+B). But what happens when that treatment fails? The optimal subsequent, or second-line, treatment strategy remains “quite open” and “undefined” in clinical practice. Now, groundbreaking real-world evidence from the multinational LEVIATHAN study is challenging previous assumptions and
LEAP-012 Trial – A New Standard of Care for Unresectable, Non-Metastatic HCC?
In a recent “Ask the Author” session, Professor Kudo discussed the LEAP-012 trial and its implications for treating hepatocellular carcinoma (HCC) with Professor Dufour. The study, titled “TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic HCC LEAP-012,” investigates a novel approach to treating this condition. Watch the Full Interview here Background
Unlocking New Insights in Hepatocellular Carcinoma: An Exclusive Interview with Prof. Andrea Casadei-Gardini
In the ever-evolving landscape of hepatocellular carcinoma (HCC) treatment, every breakthrough brings us closer to improving patient outcomes. We are thrilled to present an exclusive interview with Professor Andrea Casadei-Gardini, a leading expert in oncology, who shares pivotal findings from his recent paper, “Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to
Insights into Liver Cancer Management with Professor Ducreux
In our recent podcast lead by Prod. Jean-François Dufour, we had the privilege of speaking with Professor Michel Ducreux, a leading expert in the field of oncology from Paris, France. The discussion focused on the evolving landscape of liver cancer treatment and the latest advancements that are reshaping patient care. Below you will find the
Exploring New Frontiers in Hepatocellular Carcinoma Treatment: Insights from the CheckMate 9DW Trial
In our latest “Ask the Author” session, Professor Peter Galle presented the groundbreaking results of the CheckMate 9DW clinical trial, which explored the efficacy of the combination of nivolumab and ipilimumab versus lenvatinib or sorafenib as first-line treatments for unresectable hepatocellular carcinoma (HCC). Below you will find the video as well as the summary: Background:
Reimagining Hepatocellular Carcinoma Treatment: Insights from Professor Vitale
In a recent “Ask the Author” session, we had the pleasure of hosting Professor Vitale from the University of Padova, Italy. Renowned for his contributions to the field of hepatocellular carcinoma (HCC), Professor Vitale discussed his latest publication, “Merits and Boundaries of the BCLC Staging and Treatment Algorithm: Learning From the Past to Improve the
HCC Day 2024 quick recap
Prof. Jean-François Dufour co-organized the HCC Day 2024 related to Liver Cancer treatments end of February in Bern, Switzerland. In this short video summary, he briefly recaps the 6 lectures given by world-wide Key Opinion Leaders. If you are active in this medical field, it should be of high interest to you. All the videos
HCC 2024 Event
The HCC event in 2024 took place on the 29th of February in Bern as well as online. The videos of all the lectures can be found here
HCC 2024 Event registration
The HCC event in 2024 will be happening on the 29th of February. The program and registration can be found here